AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04831892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizer containing Colloidal Oatmeal only
Description: Vehicle lotion containing 0.1% colloidal oatmeal.
Study NCT05909462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine
Description: ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection
Study NCT05613192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
Study NCT05613192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
Study NCT05155410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exogenous Ketone Monoester
Description: Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
Study NCT05155410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
Study NCT05148559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder Sent Via Preferred Method of Communication
Description: Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
Study NCT05148559 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reminder Sent Via Mailed Letter
Description: Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
Study NCT06283303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011 hepatic artery infusion
Description: The study was divided into two dose groups, T3011 3×10\^8 PFU/time (HAI) and T3011 1×10\^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.
Study NCT06283303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: The combination therapy period: toripalimab, 80mg intravenous ,D2 and D16, 4 weeks per cycle
Study NCT06283303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: The combination therapy period: regorafenib ,80mg orally once a day, D1-D21,4 weeks per cycle
Study NCT05141565 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04873895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib 5 MG
Description: axitinib 5 mg po BID until progression or intolerance
Study NCT04873895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Pill
Description: hydroxychloroquine 600 mg po BID until progression or intolerance
Study NCT04873895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans arterial chemoembolization
Description: segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
Study NCT06258356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: novel ultra-short-acting benzodiazepine-like anesthetic.
Study NCT06258356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline (compared to Remimazolam)
Study NCT05954806 — intervention group
Intervention type: DRUG
Intervention: Antivenom Snakes
Description: No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
Study NCT05496257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: direct pulp capping in primary molars
Description: caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
Study NCT05392010 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05114798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
Study NCT05114798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
Study NCT05576870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant based toddler nutrition
Description: Plant based toddler nutrition fed daily ad libitum
Study NCT05576870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy based toddler nutrition
Description: Commercially available toddler nutrition fed daily ad libitum
Study NCT06293495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma 3 Nail (Stryker)
Description: Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)
Study NCT06293495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chimaera Nail (Orthofix)
Description: Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)
Study NCT05273918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitivo-comportmental therapy
Description: 15 workshops once a week during 90 minutes
Study NCT05273918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: body mediation
Description: 15 workshops once a week during 90 minutes
Study NCT06393946 — intervention group
Intervention type: DRUG
Intervention: Dupilumab
Description: This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
Study NCT06277609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996
Description: Capsule
Study NCT06277609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Tablet
Study NCT06277609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic Acid
Description: Tablet
Study NCT06277609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Description: Tablet
Study NCT05076552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACH101
Description: Orally via capsules
Study NCT05686876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
Study NCT04964375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK043 oral capsule
Description: ABSK043 is a novel, oral small molecule inhibitor of PD-L1
Study NCT02837601 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AirSeal® Insufflation System (AIS)
Description: The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
Study NCT04056910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivosidenib and nivolumab
Description: Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events.~Nivolumab will be administered at 480 mg IV every 28 days.
Study NCT05536986 — intervention group
Intervention type: OTHER
Intervention: Stressors
Description: Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
Study NCT05499312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKIIM-KU formula
Description: Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
Study NCT05499312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
Study NCT05601284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
Study NCT05601284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive relaxation training
Description: PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
Study NCT05501730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra QPlus System
Description: Coagulation monitoring system
Study NCT06361485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lumbar Injections with 10cc's of Wharton's Jelly Allograft
Description: Low Back Injections with Minimal Manipulation Umbilical Cord Tissue
Study NCT05916014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists
Description: Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
Study NCT05623098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: dietary fiber nutrients
Description: Whether to add nutrients containing dietary fiber
Study NCT06076616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation and rehabilitation
Description: A personalized lifestyle counseling programme.
Study NCT05538702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)
Description: Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
Study NCT05538702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)
Description: Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
Study NCT05538702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marlboro Gold (Conventional cigarette)
Description: Conventional cigarette
Study NCT05538702 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IQOS 3.0 DUO turned off with a bland taste unit
Description: Placebo device
Study NCT05895747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose 5-hydroxytryptophan
Description: 5-hydroxytryptophan 100mg PO BID
Study NCT05895747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose 5-hydroxytryptophan
Description: 5-hydroxytryptophan 200mg PO BID
Study NCT05895747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Creatine Monohydrate
Description: Creatine monohydrate 5g PO qday
Study NCT05895747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Creatine Monohydrate
Description: Creatine monohydrate 10g PO qday
Study NCT05895747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
Study NCT05761405 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mannitol-enhanced aminoglycoside
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes.
Study NCT05761405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxon
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes.
Study NCT05761405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
Study NCT05474924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide intrapolyp injection
Description: intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids
Study NCT05474924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal wash
Description: Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.
Study NCT05474924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone tablets
Description: oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
Study NCT05895747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
Study NCT06460220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Alternatives for Teens and Youth - Parent (SAFETY-P)
Description: The parent component of SAFETY focuses on enhancing parents' skills in supporting youth safety and managing parental distress during a suicidal crisis, ideal content to adapt for web-based delivery for parents. Specifically, parent information includes psychoeducation about suicide risk and protective factors, lethal means restriction, development of a parent distress tolerance plan (i.e., Parent Safety Plan), parent self-care and sources of support, strengthening the youth/parent relationship, and focus on care linkage for the youth. The SAFETY-P asynchronous parent intervention module will include text, interactive handouts, vignettes, and short video examples. The SAFETY-P module will allow for parents to access information and skills training on their own time, with the opportunity and encouragement to ask informed questions of their child's clinician; this will provide clinicians the opportunity to utilize their check-ins with parents more effectively to address youth safety.
Study NCT06460220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual (TAU)
Description: TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.
Study NCT06460220 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment As Usual (TAU)
Description: TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.
Study NCT05912894 — intervention group
Intervention type: PROCEDURE
Intervention: Videolaparoscopic cholecystectomy
Description: Evaluation of Rouvière's Sulcus Anatomical Variation.
Study NCT06251466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iHealth Gluco-Smart application
Description: iHealth Gluco-Smart is an application where blood glucose measurements can be registered. This application can be coupled to a platform in the hospital, called Dharma, that enables the researchers to evaluate these blood glucose levels.
Study NCT05489354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth psychoeducational intervention
Description: The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
Study NCT04674111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)
Description: The Vortex System is intended to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
Study NCT06024616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARANG
Description: TARANG is aimed to empower young women to navigate newly formed relationships, improve women's awareness of sexual reproductive health, and challenge inequitable gender norms, with an aim to reduce unintended pregnancies and increase use of family planning. The TARANG intervention for newly married women will include 14 group sessions delivered by trained moderators from Vikalp. It will cover three overarching themes, including norms, empowerment, and sexual and reproductive health and wellbeing.~Four light-touch sessions for mothers-in-law and one in-person session for husbands of newly married women will be conducted. For husbands, TARANG will include one 2-hour group session within the first month of the intervention, followed by regular and moderated content delivery via videos and take-home exercises over WhatsApp groups. Vikalp will conduct door-to-door listing, and a research team from NEERMAN will recruit households into the study depending on the eligibility criteria.
Study NCT05083884 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.